companydata.dkCONTERA PHARMA A/S: Financial statements 2018
CVR: 33062214
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 1,519,395 and a net result of DKK -967,629 compared with DKK -418,534 the year before. That is an increase of 7.1% compared with the year before. Equity amounted to DKK 3,202,731. The solvency ratio was 88%. The company had 2 employees in the financial year.
- Gross Profit
- 1,519,395 kr.
- Profit/Loss
- -967,629 kr.
- Equity
- 3,202,731 kr.
- Total Assets
- 3,638,605 kr.
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 1.5 mio. | -968 t. | 3.2 mio. | 2 |
| 2017 | - | 1.4 mio. | -419 t. | 1 mio. | 2 |
| 2016 | - | 3.1 mio. | 866 t. | 1.5 mio. | - |
| 2015 | - | 445 t. | -1.1 mio. | 601 t. | - |
| 2014 | - | -126 t. | -3.2 mio. | 1.7 mio. | - |
Keep an eye on CONTERA PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
As of June 30, 2018, Mikael Søndergaard Thomsen has stepped down as director of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2017. Gross profit came to DKK 1,418,538, and the net result was DKK -418,534.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee. In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity amounted to DKK 79,471,802.